Sigyn Therapeutics, Inc. (SIGY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-25K 0 25K 50K 75K Q4 '18: -1 Q1 '19: 41.6K Q2 '19: 64.3K Q3 '19: 32.1K Q4 '19: 5.3K Q1 '20: 756 Q2 '20: 0 Q3 '20: 3.8K Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20

Gross Profit Quarterly

-20K 0 20K 40K 60K Q4 '18: -1 Q1 '19: 32.3K Q2 '19: 47.5K Q3 '19: 24.1K Q4 '19: 3.8K Q1 '20: 493 Q2 '20: 0 Q3 '20: 2K Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20

Operating Income Quarterly

-900K -600K -300K 0 300K 600K 900K Q4 '23: -717.2K Q1 '24: -630K Q2 '24: -602.8K Q3 '24: -808.5K Q4 '24: -478K Q1 '25: -546.1K Q2 '25: -469.5K Q3 '25: -386.5K Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

Net Income Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q4 '23: -1.2M Q1 '24: -758.1K Q2 '24: -862.4K Q3 '24: -1.2M Q4 '24: -522.8K Q1 '25: -668.6K Q2 '25: -1.5M Q3 '25: -578.5K Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

Cost of Revenue Quarterly

0 6K 12K 18K Q4 '18: 0 Q1 '19: 9.2K Q2 '19: 16.8K Q3 '19: 8K Q4 '19: 1.6K Q1 '20: 263 Q2 '20: 0 Q3 '20: 1.8K Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20

Operating Cash Flow Quarterly

-300K -150K 0 150K 300K 450K Q4 '23: -127.9K Q1 '24: -235.6K Q2 '24: -182.8K Q3 '24: -163.8K Q4 '24: -290.2K Q1 '25: -294.4K Q2 '25: -152.4K Q3 '25: -199.3K Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

Free Cash Flow Quarterly

-600K -400K -200K 0 200K 400K 600K Q4 '17: -219K Q4 '18: 10.2K Q1 '21: -277.3K Q2 '21: -407.1K Q3 '21: -557K Q4 '21: -562K Q3 '22: -524.2K Q4 '22: -451.8K Q4 '17 Q4 '18 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q3 '22 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600K 1.2M 1.8M Q2 '23: 1.1M Q3 '23: 1.1M Q1 '24: 1.2M Q2 '24: 1.2M Q3 '24: 1.3M Q1 '25: 1.6M Q2 '25: 1.6M Q3 '25: 1.6M Q2 '23 Q3 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '23: -3.82 Q1 '24: -3.05 Q2 '24: -3.08 Q3 '24: -3.20 Q4 '24: -2.51 Q1 '25: -2.31 Q2 '25: -2.51 Q3 '25: -1.93 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.